According to the MedTech Half-Year Review, issued by
EPVantage, 2014 has been telling an optimistic story for the medical device
sector.
Some points of this report have to be mentioned:
merger and acquisitions stands at US$27.2 billion, compared to US$19 billion of
2013. The report also notes that the value of M&A in 2013 was close to
being the lowest in a decade. More merger and acquisitions are to be announced
until the end of 2014/beginning of 2015. During the first six months of 2014,
medtech venture capital investments stand at US$1.9 billion, less than half of
the US$3.9 billion raised in all of 2013. But second quarter of venture capital
investment was up 33% from the first quarter of the year, so the expectations
are still high. FDA approvals are also moving very fast. For PMAs, the average
review time was 18.4 months compared to the average of 35.9 months in 2013.
References:http://www.mddionline.com/article/5-points-showing-why-medtech-having-great-2014-so-far
No comments:
Post a Comment